Tevogen Bio Provides Clarity on CSO Share Sales to Satisfy Tax Obligations, Expects Additional Forecast and Progress Updates in the Coming Days

Rhea-AI Summary

Tevogen Bio (Nasdaq: TVGN) has clarified that the recent sale of shares by Chief Scientific Officer Dr. Neal Flomenberg was solely to satisfy tax obligations related to vesting restricted stock units, not a discretionary decision. The company's CFO, Kirti Desai, emphasized that other officers holding over 75% of outstanding shares have already paid taxes on granted shares and have no further obligation for similar sales. None of the company's officers have reduced their holdings since inception.

Tevogen recently released top-line revenue projections for its oncology therapeutic area, forecasting $1 billion in revenue for the launch year of its lead product candidate, with a 5-year cumulative estimate between $10-14 billion. The company plans to release similar forecasts for non-oncology areas soon. CEO Dr. Ryan Saadi highlighted the leadership team's retention of 100% equity as a sign of confidence in the company's potential, noting the significant market activity with over half a billion shares traded last week.

Positive

• Projected $1 billion revenue in launch year for lead oncology product
• Estimated 5-year cumulative revenue of $10-14 billion for oncology therapeutic area
• Company officers retain 100% of their equity, demonstrating confidence in the company
• High trading volume with over half a billion shares traded in a week

Negative

• CSO sold shares to meet tax obligations, potentially impacting investor perception

Insights

Financial Analyst

The CSO's share sale to meet tax obligations is a routine event and doesn't signal a lack of confidence in the company. The retention of shares by other key executives, who collectively hold over 75% of outstanding shares, is a strong vote of confidence in Tevogen's future.

The company's revenue projections are ambitious, forecasting $1 billion in the launch year for its lead oncology product and $10-14 billion cumulative over 5 years. These figures suggest significant market potential but also carry execution risks. Investors should closely monitor the upcoming non-oncology revenue forecasts and any progress updates on clinical trials or regulatory milestones.

The high trading volume of over 500 million shares last week indicates strong market interest, but also potential volatility. As a clinical-stage biotech, Tevogen's value is largely based on future potential rather than current earnings, making it a higher-risk investment. Investors should carefully consider their risk tolerance and the company's progress in bringing its T cell therapeutics to market.

Biotech Research Analyst

Tevogen's focus on off-the-shelf, genetically unmodified T cell therapeutics for infectious diseases and cancers places it in a promising niche within the immunotherapy market. The company's approach could potentially offer advantages in manufacturing scalability and cost-effectiveness compared to personalized cell therapies.

The projected $1 billion revenue for the lead oncology product's launch year is ambitious and suggests a large addressable market. However, achieving this will depend on factors such as efficacy data, regulatory approval, pricing strategy and market adoption. The cumulative 5-year estimate of $10-14 billion implies sustained growth and market penetration.

Investors should look for upcoming clinical trial results, regulatory interactions and partnerships that could validate Tevogen's technology platform. The planned release of revenue forecasts for non-oncology areas will provide a more comprehensive view of the company's potential across multiple therapeutic areas. As with any clinical-stage biotech, the path to commercialization carries significant risks and uncertainties.

WARREN, N.J., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, reported last week that Chief Scientific Officer (CSO) Dr. Neal Flomenberg sold shares. Tevogen's Chief Financial Officer, Kirti Desai, clarified that the sale was made solely to satisfy the payment of tax obligations relating to the vesting of restricted stock units and was not made at the discretion of the CSO.

Other officers, the Chief Executive Officer, the Chief Financial Officer, and the Chief Commercial Officer, who hold more than 75% of total outstanding shares in aggregate, have already paid taxes when shares were granted and have no further obligation to make similar share sales. Additionally, none of the company’s officers have decreased their holdings since the company’s inception.

In a related update, Tevogen Bio recently released top-line revenue projections for its oncology therapeutic area, anticipating $1 billion in revenue in the launch year for its lead product candidate, with a cumulative 5-year estimate ranging between $10 billion and $14 billion. The company plans to release similar revenue forecasts for its non-oncology therapeutic areas in the coming days.

"The leadership team’s retention of 100% of their equity reflects our collective confidence in the company’s potential," said Tevogen CEO Dr. Ryan Saadi. "With over half a billion shares traded on the open market last week, I am deeply grateful for the public’s unprecedented support of Tevogen’s innovative business model."

About Tevogen Bio

Tevogen is a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, aiming to address the significant unmet needs of large patient populations. Tevogen leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents and numerous pending patents, two of which are related to artificial intelligence.

Tevogen is driven by a team of experienced industry leaders and scientists with drug development and global product launch experience. Tevogen’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.

Forward Looking Statements

This press release contains certain forward-looking statements, including without limitation statements relating to: expectations regarding the healthcare and biopharmaceutical industries; Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases, cancer and neurological disorders, including TVGN 489 for the treatment of COVID-19 and Long COVID; Tevogen’s ability to develop additional product candidates, including through use of Tevogen’s ExacTcell platform; the anticipated benefits of ExacTcell; expectations regarding Tevogen’s future clinical trials; and Tevogen’s ability to generate revenue in the future. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.

Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the effect of the recent business combination with Semper Paratus Acquisition Corporation (the “Business Combination”) on Tevogen’s business relationships, operating results, and business generally; the outcome of any legal proceedings that may be instituted against Tevogen; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; costs related to the Business Combination and the failure to realize anticipated benefits of the Business Combination; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; the ability to develop, license or acquire new therapeutics; that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K and subsequent filings with the SEC.

You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.

Contacts

Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com

FAQ

Why did Tevogen Bio's CSO Dr. Neal Flomenberg sell shares?

Dr. Flomenberg sold shares solely to satisfy tax obligations related to the vesting of restricted stock units, not as a discretionary decision.

What are Tevogen Bio's (TVGNW) revenue projections for its oncology therapeutic area?

Tevogen Bio projects $1 billion in revenue for the launch year of its lead oncology product, with a 5-year cumulative estimate between $10-14 billion.

Have any Tevogen Bio officers reduced their holdings since the company's inception?

No, none of Tevogen Bio's officers have decreased their holdings since the company's inception.

What percentage of Tevogen Bio's outstanding shares are held by its top officers?

The CEO, CFO, and CCO collectively hold more than 75% of Tevogen Bio's total outstanding shares.